Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
TScan Therapeutics, Inc. - Common Stock
(NQ:
TCRX
)
1.330
+0.070 (+5.56%)
Streaming Delayed Price
Updated: 11:12 AM EDT, Apr 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about TScan Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
May 09, 2023
Via
Benzinga
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
May 09, 2023
Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease.
Via
Benzinga
TScan Therapeutics Inc. (NASDAQ: TCRX) Near the Top of Equities by Percentage Gain on 5/9
May 09, 2023
Via
Investor Brand Network
TScan Therapeutics's Return On Capital Employed Insights
↗
March 10, 2023
Via
Benzinga
Crude Oil Down 1%; Under Armour Earnings Top Views
↗
May 09, 2023
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping over 50 points on Tuesday. The Dow traded down 0.07% to 33,593.48 while the NASDAQ fell 0.52% to 12,193.35. The S&P...
Via
Benzinga
Why Are TScan Therapeutics Shares Are Shooting Higher Today
↗
May 09, 2023
Amgen Inc (NASDAQ: AMGN) and TScan Therapeutics Inc (NASDAQ: TCRX) announced a multi-year collaboration to use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recog
Via
Benzinga
TScan Therapeutics (NASDAQ: TCRX) and Amgen (NASDAQ: AMGN) Join Forces to Battle Crohn’s Disease
May 09, 2023
TScan Therapeutics, Inc. (NASDAQ: TCRX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development
Via
Spotlight Growth
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
May 09, 2023
Via
Benzinga
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
May 09, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting
May 02, 2023
Company to host a virtual event to discuss highlights from its Phase 1 umbrella trial of TSC-100 and TSC-101 on Wednesday, May 17, 2023, at 5:30 p.m. ET
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
May 02, 2023
Via
Benzinga
TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors
April 10, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces CEO Transition
March 31, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
March 14, 2023
Via
Benzinga
TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies
March 14, 2023
Patient treated with TSC-101, the first clinical cell therapy product targeting minor histocompatibility antigen HA-2 to treat leukemia and prevent relapse following hematopoietic cell transplantation
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics to Participate in the Barclays Global Healthcare Conference
March 13, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones
March 08, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
March 01, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference
February 21, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
January 25, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
↗
January 24, 2023
We're starting the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday morning!
Via
InvestorPlace
TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors
January 23, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress
January 05, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022
December 12, 2022
Poster presents Phase 1 trial design and translational assays to generate early evidence of biological activity in residual leukemia after hematopoietic cell transplantation
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe
December 01, 2022
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics to Participate in the 5th Annual Evercore ISI HealthCONx Conference
November 22, 2022
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting
November 11, 2022
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 09, 2022
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Upcoming Virtual Investor Event
November 07, 2022
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Upcoming Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
November 03, 2022
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
